

DAFTAR PUSTAKA

1. **Abdurachman. S. A.**, 2002. Hepatitis Virus Kronik. Dalam: Noer. S, editor: *Ilmu Penyakit Dalam*. Jilid 1. Edisi 3. Jakarta: Gaya Baru. Hal 262-70
2. **Akbar. N.**, 2002. Kelainan Enzim pada Penyakit Hati. Dalam: Noer. S, editor: *Ilmu Penyakit Dalam*. Jilid 1. Edisi 3. Jakarta : Gaya Baru. Hal 238-42
3. **Biron. C. A., Sen. G. C.**, 2000. Interferons and other cytokines. *Fundamental Virology*
4. **Boinot. J. K., Wu. T. T.**, 1996. Liver and Gallbladder. In: Epstein. J. I., editors: *Surgical Pathology CD-Room*. John Hopkins University Press
5. **Bratawidjadja. K. G.**, 2001. *Imunologi Dasar*. Edisi 4. Jakarta: Gaya Baru. Hal. 9, 249
6. **Brooks. G. F., Butel. J. S., Morse. S. A., Jawetz. E., Melnick. J. L., Adelberg. E. A.**, 2001. *Medical Microbiology*. 22nd ed. Philadelphia: Appleton & Lange. P. 403-17
7. **Chow. W. C. et al**, 1998. Re-treatment with interferon alfa of patients with chronic hepatitis C (abstract). *J. Hepatology* 4(27): 1144 – 8
8. **Chung. R. T., Podolsky. D. K.**, 2001. Cirrhosis and its complications. In : Braunwald. E., et al, editors : *Harisson's Principle of Internal Medicine CD Room*, 15th ed. The McGraw-Hill Medical Publishing Division
9. **Collier. L., Oxford. J., Pipkin. J.**, 2000. *Human Virology*. 2nd ed. London: Oxford University Press. P. 169-70
10. **Crawford. J. .M.**, 1999. The Liver and The Biliary Tract. In : Cotrans R.S., Kumar V., Collins T., editors: *Robbin's Pathologic Basis of Disease*. 6th ed. Philadelphia : W.B. Saunders Company. P. 846-61
11. **Dianzani. F., Baron. S.**, 2000. Nonspecific defenses. Available from: <http://www.gsbs.utmb.edu/microbook/ch049.html>
12. **Dienstag. J. L., Isselbacher. K. J.**, 2001. Acute Viral Hepatitis. In : Braunwald. E., et al, editors : *Harisson's Principle of Internal Medicine CD Room*, 15th ed. The McGraw-Hill Medical Publishing Division

13. **Dienstag. J. L., Isselbacher. K. J.**, 2001. Chronic Hepatitis. In : Braunwald. E., et al, editor: *Harisson's Principle of Internal Medicine CD Room*, 15th ed. The McGraw-Hill Medical Publishing Division
14. **Fargion. et al**, 2003. Peginterferon alfa-2a (40kd) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs inductions therapy with interferon alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV nonresponders patients with chronic hepatitis C (CHC) (abstract). Available from : <http://www.hivandhepatitis.com/2003icr/38easl/docs/032103d.html>
15. **Fried. M. W. et al**, 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infections (abstract). *N Engl J Med*, 347 (13): 975-82.. Available from: <http://content.nejm.org/cgi/content/short/347/13/975>
16. **Hadi S**, 1999. *Gastroenterologi*. Edisi 7. Bandung: Penerbit Alumni. Hal 517-26
17. **Hasan. A.**, 2002. Pengobatan Hepatitis Kronik dengan Interferon. Dalam: Noer. S., editor: *Ilmu Penyakit Dalam*. Jilid 1. Edisi 3. Jakarta: Gaya Baru. Hal: 317-22
18. **Hepatitis factsheet**, 2003. Interferons. Available from: <http://www.hepcvets.com/drug/interferons.html>
19. **Husada. Y.**, 2002. Fisiologi dan Pemeriksaan Biokimiawi Hati. Dalam: Noer. S., editor : *Ilmu Penyakit Dalam*. Jilid 1. Edisi 3. Jakarta: Gaya Baru. Hal 224-30
20. **Iqbal. M.**, 2002. An update on the management of hepatitis C. Available from: <http://hepcvets.com/hepc/update.html>
21. **Koff. R. S.**, 1998. Chronic Hepatitis C. The McGraw-Hill Companies. Available from: <http://www.hosppract.com/issues/1998/06/cekoff.htm>
22. **Mangia. A.**, 2003. A randomised controlled trial on pegylated interferon alfa-2a (40KD) (Pegasys) or IFN alfa-2a (Roferon-A) plus ribavirin (RBV) and amantadine (AMA) vs IFN alfa-2a and RBV in naive patients with chronic HCV). Available from: <http://www.hivandhepatitis.com/2003icr/38easl/docs/032103a.html>
23. **Manns. M. P.**, 1998. A new approach to HCV therapy. Available from: <http://www.hepnet.com/hepc/uldh98/manns.html>
24. **Macroscopic Lever on Chronic Hepatitis C**, 1998. Available from: <http://www.medlib.med.Utah.edu/webPath/liveHTML/liver082.html>

25. **Minunk. G., Assy. N.**, 1999. Consequences of chronic hepatitis C. Available from: <http://www.hepnet.com/update2.html>
26. **Nairn. R., Helbert. M.**, 2002. *Immunology for Medical Students*. London: Mosby International Ltd. Hal. 158-60
27. **Simon. S.**, 2002. Berbagai aspek diagnostik hepatitis C. *Jurnal Kedokteran Atma Jaya*. 2(1): 127 – 40
28. **Simon. S., Ali. S.**, 2002. Peranan biologi molekuler dalam menegakan diagnosis hepatitis virus. *Jurnal Kedokteran Atma Jaya*, 1(1) : 83 – 91
29. **Stites. D. P., Terr. A. I., Parslow. P. G.**, 1997. *Medical Immunology*. 9th ed. Philadelphia: Appleton & Lange. Hal. 157-58
30. **Sulaiman. A.**, 2002. Terapi standar mutakhir untuk hepatitis C kronik. Available from: http://www.papdi.or.id/Panduan/Panduan%20II%20terapi_standar_mutakhir_untuk_he.htm
31. **Sulkowski. M.**, 2002. Pegylated interferon in the treatment of patients with hepatitis C. Available from: <http://www.numedx.com/readstory.html>
32. **Tarigan. P.**, 2002. Sirosis Hati. Dalam: Noer. S, editor: *Ilmu Penyakit Dalam*. Jilid 1. Edisi 3. Jakarta: Gaya Baru. Hal: 271-79
33. **The Cancer BACUP Factsheet**. 2000. History of interferon. Available from: <http://www.cancerbacup.org.uk/>
34. **Tortora. G. J., Funke. B. R., Case. C. L.**, 2001. *Microbiology an introduction*. 7th ed. Toronto: Benjamin Cummings. Hal. 469-72
35. **Thornton. A., Honeywell. M., Hollis. A. L., Thomson. M.**, 2002. Update on hepatitis C virus. Available from: <http://www.uspharmacist.com/index.asp?show=ce>
36. **USP Dispensing Information**, 2001. *USP DI@ Drug Information for The Health Care Professional CD Room*. Englewood. Micromidex, Inc.
37. **Widjaja. S.**, 1999. *Virus Hepatitis B, C, dan G*. Jakarta: PT. Gramedia. Hal 21-35
38. **Widjaja. S., Simon. S., Ali. S.**, 2002. Hepatitis C up date. *Jurnal Kedokteran Atma Jaya*, 1(1) : 39-50

39. **Widura**, 2000. Interferon sebagai pengendali proliferasi sel. *Majalah Ilmiah Kedokteran Maranatha*, 6(17): 70-6
40. **Wilson L.M., Lester L.B.**, 1992. Hati, Saluran Empedu, dan Pangkreas. Dalam : Price S.A., Wilson L.M, editors: *Patofisiologi Konsep Klinik Proses-proses Penyakit*. Edisi 4. Jakarta: Penerbit Buku Kedokteran EGC. Hal. 439-40, 442-5
41. **World Health Organization**, 2000. Global Chronic Hepatitis C Infections. Available from: <http://www.idenix.com/hcv/hcv-overview.html>
42. **Zhang. F.**, 2003. Pegylated Interferons in the treatment of chronic hepatitis C (abstract). *Chin Med J (Engl)*, 116 (4) : 495 – 8. Available from: <http://cmbi.bjmu.edu.cn/ChinaPaper/details.asp?PubMedID=12875709>